F-AraG
Phase 2Small molecule
F-AraG is one of 123 small molecule programs targeting Patients With Solid Tumors. It is currently in Phase 2.
5
Indications
11
Total Trials
5
Active Trials
122
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1F-AraG
CCellSight Technologies, Inc.
Phase 2
Blood Taken
HHospices Civils de Lyon
Preclinical
Other Tkis
BayerPreclinical
Immunosuppressive
Chiesi Farmaceutici S.p.A.Preclinical
Huashi Baidu Granule
XXiyuan Hospital of China Academy of Chinese Medical Sciences
Preclinical
Stools
VVersailles Hospital
Preclinical
Serology Test
AAssistance Publique - Hôpitaux de Paris
Preclinical
Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Preclinical
Coronavac COVID-19 Vaccine
HHospital Moinhos de Vento
Preclinical
SARS-Cov-2 Bivalent MRNA Vaccine
AAIM Vaccine Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Imaging2 trials
Small Cell Lung Cancer1 trial
Radiation Therapy1 trial
Patients With Solid Tumors1 trial
5 more indications
Lymphoma1 trial
Squamous Cell Carcinoma1 trial
Advanced NSCLC1 trial
Non-Small Cell Lung Cancer1 trial
PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)
Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04524195·4 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-AraG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCellSight Technologies, Inc.